A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer

ABSTRACT: This is a Phase II, multicenter，randomized, two arms, open-labeled, controlled clinical trial. This trial was conducted to evaluate the efficacy and safety of bevacizumab (Avastin) plus mXELIRI compared with bevacizumab (Avastin) plus FOLFIRI as first-line treatment in patients with metastatic colorectal cancer (mCRC).

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2328450 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR